NSPR

InspireMD, Inc.

13 filings tracked

healthcarebiotechnologySMALL ($300M-2B)

Signal Magnitude Chart

bullish

bearish

neutral

Signal Timeline

neutralMay 22

Planned retirement of Board Chair Paul Stuka by 2027.

management change

40%

neutralMay 22

Planned retirement of Board Chair Paul Stuka by 2027.

management change

40%

neutralMay 22

Planned retirement of Board Chair Paul Stuka by 2027.

management change

40%

neutralMay 22

Planned retirement of Board Chair Paul Stuka by 2027.

management change

40%

neutralMay 22

Planned retirement of Board Chair Paul Stuka by 2027.

management change

40%

neutralMay 22

Planned retirement of Board Chair Paul Stuka by 2027.

management change

40%

bearishMay 7

Net loss of $13.7 million and substantial doubt about going concern status.

earnings miss

70%

bullishMay 7

Gross margin increased slightly to 20.2% due to higher-margin US direct sales.

margin expansion

30%

bearishMay 7

Voluntary recall of CGuard Prime delivery system in the US.

regulatory action

60%

neutralMay 7

Active use of $75 million ATM facility and private placements to fund operations.

capital raise

50%

bearishMay 7

Net loss of $13.7 million and substantial doubt about going concern status.

earnings miss

70%

bullishMay 7

Gross margin increased slightly to 20.2% due to higher-margin US direct sales.

margin expansion

30%

bearishMay 7

Voluntary recall of CGuard Prime delivery system in the US.

regulatory action

60%

neutralMay 7

Active use of $75 million ATM facility and private placements to fund operations.

capital raise

50%

bearishMay 7

Net loss of $13.7 million and substantial doubt about going concern status.

earnings miss

70%

bullishMay 7

Gross margin increased slightly to 20.2% due to higher-margin US direct sales.

margin expansion

30%

bearishMay 7

Voluntary recall of CGuard Prime delivery system in the US.

regulatory action

60%

neutralMay 7

Active use of $75 million ATM facility and private placements to fund operations.

capital raise

50%

bearishMay 7

Net loss of $13.7 million and substantial doubt about going concern status.

earnings miss

70%

bullishMay 7

Gross margin increased slightly to 20.2% due to higher-margin US direct sales.

margin expansion

30%

bearishMay 7

Voluntary recall of CGuard Prime delivery system in the US.

regulatory action

60%

neutralMay 7

Active use of $75 million ATM facility and private placements to fund operations.

capital raise

50%

bearishMay 7

Net loss of $13.7 million and substantial doubt about going concern status.

earnings miss

70%

bullishMay 7

Gross margin increased slightly to 20.2% due to higher-margin US direct sales.

margin expansion

30%

bearishMay 7

Voluntary recall of CGuard Prime delivery system in the US.

regulatory action

60%

neutralMay 7

Active use of $75 million ATM facility and private placements to fund operations.

capital raise

50%

bearishMay 7

Net loss of $13.7 million and substantial doubt about going concern status.

earnings miss

70%

bullishMay 7

Gross margin increased slightly to 20.2% due to higher-margin US direct sales.

margin expansion

30%

bearishMay 7

Voluntary recall of CGuard Prime delivery system in the US.

regulatory action

60%

neutralMay 7

Active use of $75 million ATM facility and private placements to fund operations.

capital raise

50%

bearishMay 7

Net loss of $13.7 million and substantial doubt about going concern status.

earnings miss

70%

bullishMay 7

Gross margin increased slightly to 20.2% due to higher-margin US direct sales.

margin expansion

30%

bearishMay 7

Voluntary recall of CGuard Prime delivery system in the US.

regulatory action

60%

neutralMay 7

Active use of $75 million ATM facility and private placements to fund operations.

capital raise

50%

Filing History

8-KMay 22, 2026

InspireMD's filing regarding the planned retirement of Chair Paul Stuka highlights a pivotal moment in the company's governance evolution. The event is framed as a routine succession, yet it removes a central figure from three key board committees. The ultimate impact depends on whether the Nominating and Corporate Governance Committee can attract high-caliber replacements who can navigate the company's current financial pressures and regulatory hurdles. Investors must weigh the promise of a modernized board against the risk of a leadership vacuum during a critical window of product commercialization.

10-QMay 7, 2026

The latest 10-Q reveals a company at a critical crossroads where explosive top-line growth is clashing with a looming liquidity crisis. The 122% revenue increase and successful US entry provide a clear proof of concept for the CGuard platform, yet the financial statements paint a stark picture of a business that cannot yet support its own growth. The tension between the bullish clinical validation and the bearish 'going concern' warning creates a high-risk, high-reward profile for investors. The overall impact of the filing is a mixture of commercial optimism and financial alarm. While the pipeline and market expansion are promising, the voluntary recall of the CGuard Prime delivery system adds a layer of execution risk that could stall the US rollout. Investors must weigh the potential of a $9.3 billion total available market against the immediate reality of a company that may require significant additional capital to survive the next year.